Indian Dermatology Online Journal

MUSINGS, OPINIONS, TIPS AND EXPERIENCES
Year
: 2013  |  Volume : 4  |  Issue : 1  |  Page : 52--53

Treatment of nodular scabies with topical tacrolimus


Asit Mittal, Anubhav Garg, Nidheesh Agarwal, Lalit Gupta, Ashok K Khare 
 Department of Dermatology, RNT Medical College, Udaipur, Rajasthan, India

Correspondence Address:
Asit Mittal
House No 2, Road No. 62, Ashok Nagar, Udaipur, Rajasthan
India




How to cite this article:
Mittal A, Garg A, Agarwal N, Gupta L, Khare AK. Treatment of nodular scabies with topical tacrolimus.Indian Dermatol Online J 2013;4:52-53


How to cite this URL:
Mittal A, Garg A, Agarwal N, Gupta L, Khare AK. Treatment of nodular scabies with topical tacrolimus. Indian Dermatol Online J [serial online] 2013 [cited 2021 Dec 3 ];4:52-53
Available from: https://www.idoj.in/text.asp?2013/4/1/52/105486


Full Text

Nodular scabies (NS) is a well-known clinical presentation of scabies. It presents as pruritic, persistent nodules for months even after specific treatment of scabies. [1] It probably represents the hypersensitivity reaction to retained mite parts or antigens. Genital skin and scrotal skin are the commonest sites for such lesions. The treatment for these scabietic nodules can be a challenge; they are usually treated with topical steroids or with intralesional steroids but the response is less than satisfactory and relapses are frequent, also long-term use of topical corticosteroid over genital skin can lead to significant cutaneous side effects. Tacrolimus is a calcineurin inhibitor. It binds to the FK506-binding protein leading to the inhibition of calcineurin and prevention of activation of NFAT (Nuclear Factor of Activated T cells). This blocks transcription of the gene encoding IL-2 and blocks T-cell activation and further cytokine production. Also tacrolimus inhibits the release of histamine from mast cells and basophils. [2] These actions may reduce pruritus. Various reports have shown the efficacy of tacrolimus in number of inflammatory cutaneous disorders such as psoriasis, vitiligo, oral erosive lichen planus, morphea, circinate balanitis, and seborrheic dermatitis. [2] NS often shows pseudolymphoma like histopathology with predominant T lymphocytes. [1] Pimecrolimus, another calcineurin inhibitor, has already been shown to be of benefit in NS. [3] This led us to try topical tacrolimus as a therapeutic option in NS.

Ten patients of NS were chosen. All had been adequately treated for scabies with topical permethrin and were left with persistent itchy nodular lesions on scrotal and genital skin [Figure 1] and [Figure 2]. Patients were asked to apply tacrolimus 0.03% ointment twice daily over the nodular lesions for 2 weeks. No other form of topical or systemic therapy was allowed. They were followed at weekly interval. Complete disappearance of nodular lesions with significant reduction in itching was noticed in almost all cases after 2 weeks [Figure 3] and [Figure 4]. After stopping treatment, there was recurrence of lesions in almost all patients but the lesions were smaller in size and itching was much less. A repeat course of topical tacrolimus was given for 1 week and lesions disappeared again. No further follow-up was done. Except mild burning reported by few patients, topical tacrolimus was tolerated well.{Figure 1}{Figure 2}{Figure 3}{Figure 4}

Scabietic nodules can be a real nuisance for the practitioners. Results obtained here suggest that topical tacrolimus can be a useful option in their effective management.

References

1Kerl H, Ackerman AB. Inflammatory diseases that simulate lymphomas : c0 utaneous pseuolymphomas. In: Fitzpatricks TB, Eisen AZ, Wolff K, Freedberg IM, Austen KF, editors. Dermatology in General Medicine. 4 th ed. New York: McGraw-Hill Inc.; 1993. p. 1322-3.
2Lin AN. Topical calcineurin inhibitors. In: Wolverton SE, editor. Comprehensive Dermatologic Drug Therapy. 2 nd ed. China: Saunders Elsevier; 2007. p. 671-89.
3Almeida HL Jr. Treatment of steroid-resistant nodular scabies with topical pimecrolimus. J Am Acad Dermatol 2005;53:357-8.